I wrote last month about the need to increase security for imaging devices in hospitals. The devices I cited store both personal and medical information about patients and should be subject to standard security measures. Very often they are not.
ADVERTISEMENT |
Last month the U.S. Food and Drug Administration (FDA) issued proposed guidelines for post-market management of cybersecurity in medical devices. The guidelines provide best practices for assessing and managing cybersecurity vulnerabilities in medical devices and include situations involving both hacker access to patient records and hacker access to the devices themselves. Although a hacker’s ability to access our private information is alarming, it’s even more distressing to consider a hacker’s ability to increase or decrease IV drips, alter pacemaker functions, or change settings on an imaging device.
Networked medical devices come under the broader heading of the Internet of things (IoT), which includes anything that has an on/off switch and an Internet connection. Currently, that could be everything from cell phones, coffee makers, home security systems, and baby monitors to an airplane’s jet engine or the drill on an oil rig. Gartner, an analyst firm, predicts that there will be more than 21 billion connected devices by 2020.
Security is an ongoing concern with the IoT. Every additional connection opens up another possible point of entry into networks, for legitimate users and hackers. In the rush to market to offer new features to improve ease of use or innovations in care, sometimes security is an afterthought. The FDA guidelines encourage active and ongoing evaluation of cyber risks and efforts to manage those risks for products in the marketplace.
One notable omission in the guidelines, however, is any penalty for not ensuring the security of devices. Manufacturers are under no obligation to follow best practices or to change their manufacturing processes at this time. I expect competition in the marketplace will handle some reluctance to adopt the guidelines. Penalties may handle the remainder of the reservations.
Stakeholders have 90 days to submit comments to the FDA before the guidelines are finalized.
Add new comment